AlphAIAlphAI — Financial news for AI agents
Stock TitanMAY 223 min read$IMCR

69,271 ADRs sale scheduled by Immunocore (NASDAQ: IMCR)

Immunocore Holdings Plc has filed to sell 69,271 ADRs through a same-day cashless exercise and sale scheduled for May 26, 2026, with cash settlement brokered by J.P. Morgan Securities LLC. The filing also details recent sales by David Berman, including 11,832 ADRs sold on March 11, 2026, 25,000 on April 8, 2026, and 65,000 on May 21, 2026. The transaction is reported as having a neutral filing impact and sentiment, outlining key figures and definitions related to the Form 144 filing process.

Original reporting
Stock Titan
Published May 22, 2026, 7:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 22, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$IMCR
Neutral
medium confidence
Mentioned
$IMCR
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$IMCRNeutralLow
01

Why it matters

The scheduled sale and recent insider sales are typical and do not necessarily signal negative prospects. Investors should consider this in conjunction with other fundamental and technical indicators.

02

Market read

The activity is company-specific with limited broader market implications.

03

What to watch

Market reaction may be muted if overall biotech sector sentiment remains positive; broader market conditions could overshadow company-specific news.

Relevance 6/10Timing: short-term

Background

Immunocore Holdings Plc is a biotech company involved in developing immunotherapies. Insider sales are common during scheduled liquidity events.

Company-level read

Ticker impact

$IMCRNeutralMedium confidence
Context

The filing pertains to a scheduled sale of 69,271 ADRs by Immunocore Holdings Plc, with recent sales by a key insider, David Berman, indicating potential insider activity.

Expected impact

Minimal immediate impact; potential slight downward pressure if market perceives insider sales as a sign of profit-taking.

Evidence & confidence

Insider sales are within normal ranges and are scheduled, indicating planned liquidity needs rather than distress. No significant news or earnings reports accompany this filing.

Market effects

Sector

Limited; the sale pertains specifically to Immunocore's stock and does not indicate sector-wide issues.

Regional

Minimal; the activity is localized to the company's primary market.

Global

Low; the transaction is company-specific and does not influence global markets.

Counterpoint

What could challenge this read

Insider sales may be routine and not indicative of negative outlook; the company could be diversifying or meeting liquidity needs without signaling distress.

Key entities

  • Company
    Immunocore Holdings Plc

    A biotechnology company specializing in immunotherapies.

  • Insider
    David Berman

    A key insider who has sold shares on multiple occasions.

Read at source← All news

Related articles

SEP 14
$IMCRMedAI 8/10

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Immunocore Holdings plc (IMCR) filed an SEC Form 8-K — Regulation FD Disclosure. Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK ® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US,

SEC EDGAR 8-K2 min
AUG 6
$IMCRMed

Immunocore reports second quarter financial results and provides a business update

Immunocore Holdings plc (IMCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Immunocore reports second quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma nearing

SEC EDGAR 8-K7 min
MAY 31
$IMCRMedAI 9/10

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Immunocore reported updated Phase 1/2 brenetafusp data in heavily pretreated HLA-A*02:01-positive advanced melanoma at ASCO 2026. In 66 monotherapy patients, 6-month OS was 87% and disease control rate 52% (ORR 12%); median OS was 14.3 months. The company said results supported a 160 mcg dose for Phase 3 PRISM-MEL-301 and that safety was generally well tolerated.

manilatimes.net5 min
OCT 24
$CLYMHighAI 8/10

Climb Bio reports early data on budoprutug for kidney diseases

Climb Bio (CLYM) presented Phase 2 trial data for budoprutug, an anti-CD19 antibody, showing B-cell depletion and PLA2R antibody reductions in kidney disease patients. The 200 mg dose achieved 70% mean antibody reduction, with 5/13 patients in remission. The 600 mg dose showed deeper B-cell depletion. The drug was well-tolerated. Climb Bio expects more data in 2027. Primary membranous nephropathy affects 75,000 people in the U.S. without FDA-approved treatments.

investing.com2 min